Neumora Therapeutics, Inc.
NMRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNeumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in. Valued at $337.2M, NMRA is a small-cap name in its sector. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Market Cap
$337.2M
Beta
3.05
P/E (TTM)
—
P/E (Fwd)
-2.04
EPS (TTM)
$-1.33
EPS (Fwd)
$-0.89
ROE
-121.2%
ROA
-58.1%
Cash
$182.5M
Total Debt
$55.0M
Free CF
-$115.7M
52W Change
144.9%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $182.5M in cash comfortably exceeding the $55.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$115.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -121.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
With a beta above 1.5, NMRA tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. With cash comfortably exceeding debt, NMRA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Neumora Therapeutics, Inc.'s trajectory.